Sandra Kostyk
Neurology · Columbus, OHNPI 1043394810
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,800 of the $14,208 with a category attached, or 97.1%. Genentech, Inc. accounts for 97.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $13,800 and has fallen 97.8% since, to $309 in 2024.
Across 8 payments — averaging $1776.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$14K
- Alnylam Pharmaceuticals Inc.$309
- E.r. Squibb & Sons, L.L.C.$99
Across 84 payments — averaging $6656.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$527K
- Alnylam Pharmaceuticals Inc.$28K
- H. Lundbeck A S$5K
What the payments were for
- Consulting fees$13,80097%
- Travel & lodging$1771%
- Food & beverage$2322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 2 | $13,800 |
| Alnylam Pharmaceuticals Inc. | 5 | $309 |
| E.r. Squibb & Sons, L.L.C. | 1 | $99 |
How this compares
$14,208 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $165,206 |
| IngrezzaValbenazine Tosylate | 12 | $100,415 |
| Tetrabenazine | 12 | $69,510 |
| Aripiprazole | 35 | $3,341 |
| AmantadineAmantadine Hcl | 63 | $2,593 |
| Glycopyrrolate | 14 | $2,096 |
| Doxepin Hcl | 26 | $2,011 |
| Quetiapine Fumarate | 34 | $1,853 |
| Oxybutynin Chloride ErOxybutynin Chloride | 60 | $1,473 |
| Buspirone Hcl | 104 | $1,438 |
| Sertraline Hcl | 76 | $1,031 |
| Risperidone | 73 | $919 |
| Olanzapine | 46 | $872 |
| Haloperidol | 29 | $743 |
| Baclofen | 33 | $537 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbus
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Jacqueline NicholasColumbus$743K
- Geoffrey EubankColumbus$508K
- Jerry MendellColumbus$315K
- Andrew SmithColumbus$254K
- Douglas ScharreColumbus$191K
- Aristide MerolaColumbus$133K
- Miriam FreimerColumbus$105K
- Allison JordanColumbus$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.